Table 1. Patient characteristics based on type of treatment.
| Clinical characteristic | Surgery-only, n=24 (%) | Surgery plus IMRT, n=14 (%) | P |
|---|---|---|---|
| Age (years) | |||
| ≤60 | 16 (66.7) | 12 (85.7) | 0.268 |
| >60 | 8 (33.3) | 2 (14.3) | |
| Sex | |||
| Men | 10 (41.7) | 8 (57.1) | 0.357 |
| Women | 14 (58.3) | 6 (42.9) | |
| Hepatitis status | |||
| HBV (+) | 6 (25.0) | 3 (21.4) | 1 |
| HCV (+) | 0 (0) | 1 (7.1) | 0.368 |
| Pretreatment CEA (ng/mL) | |||
| ≤5.0 | 15 (62.5) | 10 (71.4) | 0.379 |
| >5.0 | 6 (25.0) | 1 (7.1) | |
| Unknown | 3 (12.5) | 3 (21.4) | |
| Tumor distribution | |||
| Solitary | 22 (91.7) | 12 (85.7) | 0.616 |
| Multifocal | 2 (8.3) | 2 (14.3) | |
| Tumor size (cm) | |||
| ≤5.0 | 14 (58.3) | 10 (71.4) | 0.42 |
| >5.0 | 10 (41.7) | 4 (28.6) | |
| Tumor grade | |||
| Well differentiated | 0 (0) | 0 (0) | 0.313 |
| Moderately differentiated | 12 (50.0) | 6 (42.9) | |
| Poorly differentiated | 9 (37.5) | 8 (51.7) | |
| Unknown | 3 (12.5) | 0 (0) | |
| Tumor stage (AJCC, 7th ed) | |||
| Stage I | 5 (35.7) | 8 (33.3) | 0.794 |
| Stage II | 1 (7.1) | 2 (8.3) | |
| Stage III | 4 (28.6) | 4 (16.7) | |
| Stage IVA | 4 (28.6) | 10 (41.7) | |
| Lymph node involvement | |||
| Negative | 14 (58.3) | 11 (78.6) | 0.294 |
| Positive | 10 (41.7) | 3 (21.4) |
HBV, hepatitis B virus; HCV, hepatitis C virus; CEA, carcinoembryonic antigen; AJCC, American Joint Committee on Cancer; IMRT, intensity-modulated radiotherapy.